Business Context and Reporting Period
This Form 8-K was filed by Karyopharm Therapeutics Inc. on December 23, 2013, reporting events that occurred on December 18, 2013. The filing addresses Item 5.02 regarding the appointment of principal officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
- Stock Price: $23.66 per share (closing price on December 18, 2013).
- Executive Stock Options Granted:
- Michael G. Kauffman (CEO): 140,000 shares.
- Sharon Shacham (President and CSO): 140,000 shares.
- Paul Brannelly (SVP, Finance): 46,000 shares.
- Option Terms: All options have an exercise price of $23.66, vest 25% on the first anniversary, and the remainder vests in equal increments over 36 months.
Material Changes and Compensation Adjustments
The filing details approved compensation adjustments for 2013 bonuses and 2014 salaries for three key executives:
- Michael G. Kauffman: 2013 performance bonus of $170,000; 2014 annual salary of $440,000.
- Sharon Shacham: 2013 performance bonus of $129,342; 2014 annual salary of $385,000.
- Paul Brannelly: 2013 pro-rated performance bonus of $47,724; 2014 annual salary of $285,000.
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, future outlook, management commentary on business strategy, or specific risk factors beyond the standard disclosure of executive compensation.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to assess the dilution impact of the 326,000 new options granted.
- Confirm the vesting schedule alignment with executive retention goals.
- Review the company's cash position to ensure it can fund the approved 2013 bonuses and 2014 salary increases.
- Check subsequent filings for any changes to the compensation committee's decisions or executive departures.